Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147

Publisher： Karger

E-ISSN： 1423-0232|77|2|120-123

ISSN： 0030-2414

Source： Oncology, Vol.77, Iss.2, 2009-07, pp. : 120-123

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment Outcome in Patients with Primary Central Nervous System Germ Cell Tumour: Clinical Experience from a Regional Cancer Centre in North India

By  

Pediatric Neurosurgery, Vol. 52, Iss. 4, 2017-05 ,pp. : 240-249

Karger

Access to resources Recommend Favorite

Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab – an Antibody against Epidermal Growth Factor Receptor: Systemic Review and Meta-Analysis

By  

Oncology, Vol. 77, Iss. 2, 2009-07 ,pp. : 124-133

Karger

Access to resources Recommend Favorite

The Well-Being and Personal Wellness Promotion Strategies of Medical Oncologists in the North Central Cancer Treatment Group

By  

Oncology, Vol. 68, Iss. 1, 2005-04 ,pp. : 23-32

Karger

Access to resources Recommend Favorite

Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain

By  

Oncology Research and Treatment, Vol. 35, Iss. 5, 2012-04 ,pp. : 254-258

Karger

Access to resources Recommend Favorite

Mizoribine Treatment of Young Patients with Severe Lupus Nephritis: A Clinicopathologic Study by the Tohoku Pediatric Study Group

By  

Nephron Clin Pract, Vol. 110, Iss. 2, 2008-09 ,pp. : c73-c79

Karger

Access to resources Recommend Favorite